Regression of HIV-associated pulmonary arterial hypertension and long-term survival during antiretroviral therapy
- PMID: 11835116
- DOI: 10.4414/smw.2001.09842
Regression of HIV-associated pulmonary arterial hypertension and long-term survival during antiretroviral therapy
Abstract
In a 37-year-old patient HIV infection was diagnosed in June 1986. Eight years later the patient complained of increasing shortness of breath and occasional syncopes on exertion. He developed peripheral oedema and ascites. Echocardiography revealed severe pulmonary hypertension. Right ventricular systolic pressure (RVSP) was 77 mm Hg. There was no evidence of left ventricular dysfunction, valvular heart disease, thromboembolic disease or obstructive or restrictive lung disease, nor were there other known causes or risk factors of pulmonary hypertension. HIV-associated pulmonary arterial hypertension was diagnosed. Oral anticoagulation and zidovudine were begun, but RVSP rose to 96 mm Hg. After the introduction of lamivudine, and later stavudine and nelfinavir, HIV-RNA copies decreased from 133 400 to below 50 copies per mL. Six years after the diagnosis of HIV-associated pulmonary arterial hypertension RVSP had continually fallen to 49 mm Hg and the grossly enlarged right heart dimensions had nearly normalised without vasodilator treatment. The patient remains in excellent health and his sole complaint is of mild dyspnoea on exertion.
Comment in
-
Papaverine, a vasodilator with antiviral activity.Swiss Med Wkly. 2002 Feb 23;132(7-8):105; author reply 105. doi: 10.4414/smw.2002.09951. Swiss Med Wkly. 2002. PMID: 11971205 No abstract available.
Similar articles
-
AVANTI 3: a randomized, double-blind trial to compare the efficacy and safety of lamivudine plus zidovudine versus lamivudine plus zidovudine plus nelfinavir in HIV-1-infected antiretroviral-naive patients.Antivir Ther. 2001 Jun;6(2):127-34. Antivir Ther. 2001. PMID: 11491417 Clinical Trial.
-
Antiretroviral treatment. HIV infection in adults: better-defined first-line treatment.Prescrire Int. 2004 Aug;13(72):144-50. Prescrire Int. 2004. PMID: 15532140
-
Antiviral activity of enteric-coated didanosine, stavudine, and nelfinavir versus zidovudine plus lamivudine and nelfinavir.J Acquir Immune Defic Syndr. 2002 Dec 1;31(4):399-403. doi: 10.1097/00126334-200212010-00005. J Acquir Immune Defic Syndr. 2002. PMID: 12447010 Clinical Trial.
-
HIV-Related pulmonary hypertension: analytic review of 131 cases.Chest. 2000 Oct;118(4):1133-41. doi: 10.1378/chest.118.4.1133. Chest. 2000. PMID: 11035689 Review.
-
Resolution of HIV-associated nephrotic syndrome with highly active antiretroviral therapy delivered by gastrostomy tube.Pediatrics. 1999 Dec;104(6):1394-6. doi: 10.1542/peds.104.6.1394. Pediatrics. 1999. PMID: 10585995 Review.
Cited by
-
Pulmonary Arterial Hypertension among HIV-Infected Children: Results of a National Survey and Review of the Literature.Front Pediatr. 2015 Apr 7;3:25. doi: 10.3389/fped.2015.00025. eCollection 2015. Front Pediatr. 2015. PMID: 25905096 Free PMC article. Review.
-
Drug treatment of pulmonary arterial hypertension: current and future agents.Drugs. 2005;65(10):1337-54. doi: 10.2165/00003495-200565100-00003. Drugs. 2005. PMID: 15977967 Review.
-
The Intersection of HIV and Pulmonary Vascular Health: From HIV Evolution to Vascular Cell Types to Disease Mechanisms.J Vasc Dis. 2024 Jun;3(2):174-200. doi: 10.3390/jvd3020015. Epub 2024 May 6. J Vasc Dis. 2024. PMID: 39464800 Free PMC article.
-
A novel expression of exercise induced pulmonary hypertension in human immunodeficiency virus patients: a pilot study.Open Cardiovasc Med J. 2012;6:44-9. doi: 10.2174/1874192401206010044. Epub 2012 Apr 20. Open Cardiovasc Med J. 2012. PMID: 22550549 Free PMC article.
-
Pathology of pulmonary hypertension.Clin Chest Med. 2007 Mar;28(1):23-42, vii. doi: 10.1016/j.ccm.2006.11.010. Clin Chest Med. 2007. PMID: 17338926 Free PMC article. Review.